134 results on '"Bristow, Michael R."'
Search Results
2. Left Ventricular Dysfunction in Murine Models of Heart Failure and in Failing Human Heart is Associated With a Selective Decrease in the Expression of Caveolin-3
3. Impact of Cardiac Resynchronization Therapy on Exercise Performance, Functional Capacity, and Quality of Life in Systolic Heart Failure With QRS Prolongation: COMPANION Trial Sub-Study
4. Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)
5. Influence of Diabetes on Cardiac Resynchronization Therapy With or Without Defibrillator in Patients With Advanced Heart Failure
6. Adjudication Of Cause-specific Endpoints In Heart Failure Trials
7. Rationale and Design of the Enoximone Clinical Trials Program
8. Changes in Heart Rate Variability Are Correlated to Hemodynamic Improvement With Chronic CARVEDILOL Therapy in Heart Failure
9. Increased Reactive Oxygen Species Production and Functional Alterations in Antioxidant Enzymes in Human Failing Myocardium
10. Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers
11. Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
12. Selective activation of N-Acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes
13. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium
14. Inotropes and β-blockers: Is there a need for new guidelines?
15. Predicting response to carvedilol for the treatment of heart failure: A multivariate retrospective analysis
16. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION) trial
17. β-Blockade in adriamycin-induced cardiomyopathy
18. Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy
19. Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism
20. RNA Sequencing, Microarray Hybridization, and Quantitative PCR Produce Complementary, Concordant Results in Longitudinal Analysis of Myocardial Gene Expression in Dilated Cardiomyopathy Patients
21. New Onset Atrial Fibrillation Is a Risk Factor for Ventricular Arrhythmias in Heart Failure
22. Myocardial Gene Expression Associated With Right- and Left-Ventricular Remodeling With Beta-Blockade in Idiopathic Dilated Cardiomyopathy
23. Effect of Bucindolol on Heart Failure Outcomes in HFREF Patients With Permanent Atrial Fibrillation
24. Transcriptional Profiles of Ventricular Ectopy on β-Blocker Therapy
25. Discovery and Validation of Novel Genes in Cardiac Remodeling
26. Transcriptional Profiles of Reverse Remodeling
27. Human Myocardial b 1 389 Arg/Arg Adrenergic Receptors Exhibit a Propensity for Constitutively Active, High Affinity Agonist Binding and Are Selectively Inactivated by Bucindolol
28. Down-Regulation of Connexin43 in Heart Failure Is Reversed by Beta Blocker Therapy
29. Determination of Hospitalization Type by Investigator Case Report Form or Adjudication Committee in a Large Heart Failure Clinical Trial (BEST)
30. Different Patterns of LVEF/Remodeling and Clinical Endpoint Effects for Bucindolol in b 1 -AR 389 Arg/Gly Genotypes
31. Effects of Bucindolol Enantiomers on Nitric Oxide and Peroxynitrite Release from Endothelial Cells in Ethnic Populations
32. Effect of the b 3 -Receptor Antagonist SR59230A on Bucindolol-Induced Release of Nitric Oxide and Peroxynitrite from Human Endothelium
33. Ischemic Cardiomyopathy Response to Bucindolol May Be Differentially Influenced by b 1 389 Arg/Gly and a 2c Genotypes
34. The β1Arg389 Polymorphism Increases Fetal Gene Program Expression in Human Non-Failing Male Subjects and in Neonate Rat Cardiac Myocytes
35. Gene Expression Profiles in Idiopathic Dilated Cardiomyopathies, a Validation Study
36. Assist Devices Fail To Induce Reverse Fetal-Pattern Gene Expression Despite Administration of Beta Blockers
37. YY1 is increased in human heart failure and represses the activity of the human αMyHC promoter
38. [beta ]-Blockade in adriamycin-induced cardiomyopathy
39. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material
40. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
41. Safety and efficacy of carvedilol in severe heart failure
42. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure
43. Effect of the b3-Receptor Antagonist SR59230A on Bucindolol-Induced Release of Nitric Oxide and Peroxynitrite from Human Endothelium
44. Ischemic Cardiomyopathy Response to Bucindolol May Be Differentially Influenced by b1 389 Arg/Gly and a2c Genotypes
45. Different Patterns of LVEF/Remodeling and Clinical Endpoint Effects for Bucindolol in b1-AR 389 Arg/Gly Genotypes
46. Human Myocardial b1 389 Arg/Arg Adrenergic Receptors Exhibit a Propensity for Constitutively Active, High Affinity Agonist Binding and Are Selectively Inactivated by Bucindolol
47. The β 1Arg389 Polymorphism Increases Fetal Gene Program Expression in Human Non-Failing Male Subjects and in Neonate Rat Cardiac Myocytes
48. Differential Effects of β-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy
49. Pharmacogenetic Therapeutic Enhancement of a Prespecified Composite Morbidity-Mortality Measurement in BEST
50. Influence of Lead Location on Outcomes in the COMPANION Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.